NASDAQ:WVE - Wave Life Sciences Stock Price, Forecast & News

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) posted its quarterly earnings results on Tuesday, November, 5th. The company reported ($1.48) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by $0.14. The company earned $2.93 million during the quarter, compared to the consensus estimate of $6.30 million. Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Wave Life Sciences.

Wave Life Sciences will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 analysts have issued 1-year price targets for Wave Life Sciences' stock. Their forecasts range from $10.00 to $65.00. On average, they expect Wave Life Sciences' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 181.2% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.

Media stories about WVE stock have trended very positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Wave Life Sciences earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Wave Life Sciences.

Wave Life Sciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,440,000 shares, an increase of 46.4% from the January 15th total of 4,400,000 shares. Based on an average daily trading volume, of 882,200 shares, the days-to-cover ratio is presently 7.3 days. Approximately 24.8% of the company's shares are sold short. View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Odonate Therapeutics (ODT), NextCure (NXTC), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA) and Dermira (DERM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Novavax (NVAX), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Agile Therapeutics (AGRX), Cidara Therapeutics (CDTX) and Eyepoint Pharmaceuticals (EYPT).

Wave Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.89%), Janus Henderson Group PLC (2.34%), State Street Corp (1.40%), FMR LLC (0.61%), Point72 Asset Management L.P. (0.46%) and Spark Investment Management LLC (0.38%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Spark Investment Management LLC, State Street Corp, New York State Common Retirement Fund, Bank of America Corp DE, Platinum Investment Management Ltd. and ProShare Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

WVE stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., Pictet Asset Management Ltd., Citigroup Inc., California Public Employees Retirement System, Amia Capital LLP, NJ State Employees Deferred Compensation Plan and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $8.89.

Wave Life Sciences has a market capitalization of $304.84 million and generates $14.41 million in revenue each year. The company earns $-146,650,000.00 in net income (profit) each year or ($5.06) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.View Additional Information About Wave Life Sciences.

The official website for Wave Life Sciences is http://www.wavelifesciences.com/.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]